Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial stages, with potential public health benefits but years from availability.
Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results